Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications
Open Access
- 8 March 2025
- journal article
- review article
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-24
Abstract
Epigenomic modifications—such as DNA methylation, histone acetylation, and histone methylation—and their implications in tumorigenesis, progression, and treatment have emerged as a pivotal field in cancer research. Tumors undergo metabolic reprogramming to sustain proliferation and metastasis in nutrient-deficient conditions, while suppressing anti-tumor immunity in the tumor microenvironment (TME). Concurrently, immune cells within the immunosuppressive TME undergo metabolic adaptations, leading to alterations in their immune function. The complicated interplay between metabolites and epigenomic modulation has spotlighted the significance of epigenomic regulation in tumor immunometabolism. In this review, characteristics of the epigenomic modification associated with tumors are systematically summarized alongside with their regulatory roles in tumor metabolic reprogramming and immunometabolism. Classical and emerging approaches are delineated to broaden the boundaries of research on the crosstalk research on the crosstalk between tumor immunometabolism and epigenomics. Furthermore, we discuss potential therapeutic strategies that target tumor immunometabolism to modulate epigenomic modifications, highlighting the burgeoning synergy between metabolic therapies and immunotherapy as a promising avenue for cancer treatment.Keywords
This publication has 210 references indexed in Scilit:
- Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast CancerAdvanced Science, 2024
- Targeting one‐carbon metabolism for cancer immunotherapyClinical and Translational Medicine, 2024
- BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressionsCellular and Molecular Life Sciences, 2023
- Tryptophan Metabolism Acts as a New Anti‐Ferroptotic Pathway to Mediate Tumor GrowthAdvanced Science, 2023
- Combined Single‐Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early DisseminationAdvanced Science, 2023
- Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunitiesCancer Communications, 2022
- Advances in mass spectrometry imaging for spatial cancer metabolomicsMass Spectrometry Reviews, 2022
- Sample-multiplexing approaches for single-cell sequencingCellular and Molecular Life Sciences, 2022
- Spatial omics: Navigating to the golden era of cancer researchClinical and Translational Medicine, 2022
- DDIT3 Directs a Dual Mechanism to Balance Glycolysis and Oxidative Phosphorylation during Glutamine DeprivationAdvanced Science, 2021